Giannaccare G, Bonifazi F, Sessa M, Dan E, Arpinati M, Fresina M, Bandini G, Cavo M, Versura P, Campos E C
Ophthalmology Unit, DIMES, Alma Mater Studiorum, University of Bologna, S. Orsola-Malpighi Teaching Hospital, Bologna, Italy.
Haematology Institute 'L.A. Seragnoli', DIMES, Alma Mater Studiorum University of Bologna, S. Orsola-Malpighi Teaching Hospital, Bologna, Italy.
Eye (Lond). 2017 Oct;31(10):1417-1426. doi: 10.1038/eye.2017.78. Epub 2017 May 19.
PurposeTo evaluate ocular surface parameters before and after hematopoietic stem cell transplantation (HSCT) and to correlate them with clinical and transplant variables.MethodsThis is a retrospective analysis of data from 93 patients affected by hematological malignancies undergoing HSCT. Values from Ocular Surface Disease Index, Schirmer test, Break-up Time, ocular surface staining, and Meibomian Gland Dysfunction score obtained before HSCT and 3-6 months after were retrieved from charts. Diagnosis and staging of dry eye (DE) disease was performed according to Dry Eye WorkShop criteria. Graft-versus-host-disease (GVHD) was classified according to the NIH criteria. Odds ratios for DE onset after HSCT were estimated for demographic, ocular, hematological and transplant variables.ResultsDE was diagnosed before HSCT in 50 (53%) of the patients, mostly of hyperevaporative profile. After HSCT, all ocular parameters significantly worsened with no change in DE profile. A 51% incident cases (22 of the 43 non-DE subjects) were reported. Increasing recipient age and female sex, higher CD34+ cells infused, donor-recipient sex mismatch (males receiving from females), related donors, and peripheral blood cells as stem cell source were associated with a significant higher incidence of DE after HSCT. Systemic chronic GVHD was diagnosed in 42% while ocular GVHD in 35.5% of the patients, which decreased to 12% when taking into account only incident cases.ConclusionsHigh DE prevalence was shown already before HSCT. A pre-HSCT ocular surface assessment is recommended for early DE diagnosis and treatment. This new protocol also influences the prevalence of ocular GVHD.
目的
评估造血干细胞移植(HSCT)前后的眼表参数,并将其与临床及移植变量相关联。
方法
这是一项对93例接受HSCT的血液系统恶性肿瘤患者的数据进行的回顾性分析。从病历中获取HSCT前及术后3 - 6个月的眼表疾病指数、泪液分泌试验、泪膜破裂时间、眼表染色及睑板腺功能障碍评分值。根据干眼研讨会标准进行干眼(DE)疾病的诊断和分期。移植物抗宿主病(GVHD)根据美国国立卫生研究院标准进行分类。对人口统计学、眼部、血液学及移植变量估计HSCT后DE发病的比值比。
结果
50例(53%)患者在HSCT前被诊断为DE,大多数为蒸发过强型。HSCT后,所有眼表参数均显著恶化,DE类型无变化。报告了51%的新发病例(43例非DE受试者中的22例)。受者年龄增加、女性性别、输注的CD34 +细胞数量增加、供受者性别不匹配(男性接受女性供者的移植)、相关供者以及作为干细胞来源的外周血细胞与HSCT后DE的显著更高发病率相关。42%的患者被诊断为系统性慢性GVHD,35.5%的患者被诊断为眼部GVHD,仅考虑新发病例时该比例降至12%。
结论
HSCT前已显示出较高的DE患病率。建议在HSCT前进行眼表评估以早期诊断和治疗DE。这一新方案也影响眼部GVHD的患病率。